IL2 and non-Hodgkin lymphoma: Bachanova et al. performed a phase II clinical trial in patients with refractory non-Hodgkin lymphoma (NHL), who received haploidentical NK cells with anti-CD20 antibody rituximab and IL-2 (NCT01181258) [21].